Zura Bio Limited (ZURA)
Market: NASD |
Currency: USD
Address: 1489 W. Warm Springs Road
Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development. The company is based in Henderson, Nevada.
📈 Zura Bio Limited Historical Chart
📊 Statistics
-
Analyst 1 Year Price Target:
$13.67
-
Upside/Downside from Analyst Target:
1,131.23%
-
Broker Call:
12
-
Dividend Minimum 3 Year Yield:
0.00%
-
EPS Growth Range (1Y):
50-100%
-
Net Income Growth Range (1Y):
<0%
-
Revenue Growth Range (1Y):
-
💰 Dividend History
No dividend history available.
📅 Earnings & EPS History for Zura Bio Limited
| Date | Reported EPS |
|---|
| 2026-03-23 (estimated upcoming) | - |
| 2025-11-05 (estimated upcoming) | - |
| 2025-11-04 (estimated upcoming) | - |
| 2025-08-13 (estimated upcoming) | - |
| 2025-08-12 (estimated upcoming) | - |
| 2025-05-08 | - |
| 2025-05-07 | - |
| 2025-03-26 | - |
| 2025-03-25 | -0.1 |
| 2024-11-07 | -0.26 |
| 2024-08-13 | -0.17 |
| 2024-08-12 | -0.17 |
| 2024-05-09 | -0.02 |
| 2024-05-08 | -0.02 |
| 2024-03-28 | -0.19 |
| 2024-03-27 | -0.19 |
| 2023-11-13 | -0.18 |
| 2023-11-12 | -0.18 |
| 2023-08-14 | -1.31 |
| 2023-08-13 | -1.31 |
📰 Related News & Research
No related articles found for "zura bio".
